Compare LW & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LW | CORT |
|---|---|---|
| Founded | 1950 | 1998 |
| Country | United States | United States |
| Employees | 10000 | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 9.7B |
| IPO Year | 2016 | 2001 |
| Metric | LW | CORT |
|---|---|---|
| Price | $53.86 | $119.02 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 5 |
| Target Price | $44.14 | ★ $96.50 |
| AVG Volume (30 Days) | ★ 1.8M | 1.1M |
| Earning Date | 04-01-2026 | 04-30-2026 |
| Dividend Yield | ★ 3.53% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.08 | 0.09 |
| Revenue | N/A | ★ $761,407,000.00 |
| Revenue This Year | $4.26 | $26.08 |
| Revenue Next Year | N/A | $26.98 |
| P/E Ratio | ★ $24.99 | $1,312.22 |
| Revenue Growth | N/A | ★ 12.79 |
| 52 Week Low | $37.62 | $28.66 |
| 52 Week High | $67.07 | $122.21 |
| Indicator | LW | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 60.08 | 69.04 |
| Support Level | $51.19 | $76.41 |
| Resistance Level | $55.69 | $122.21 |
| Average True Range (ATR) | 1.25 | 3.87 |
| MACD | -0.29 | 0.18 |
| Stochastic Oscillator | 57.55 | 89.16 |
Lamb Weston is North America's largest and the world's second-largest producer of branded and private-label frozen potato products, both by volume and value. The company's portfolio is anchored by french fries, but it also sells sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. Roughly two thirds of revenue comes from its home market of North America, with none of the other 100 countries the company sells into representing a significant share. McDonald's is Lamb Weston's single-largest customer at 15% of fiscal 2025 sales, with no other company representing more than 10%. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.